Featured news from NHIVNA

HIV-related news from NAM

Integrase inhibitors not causing higher rates of adverse birth outcomes, Botswana and French studies show
Carole Leach-Lemens, 2017-07-25 12:20:00

Dolutegravir-based antiretroviral therapy (ART) started in pregnancy is as safe as efavirenz-based ART, according to a study of birth outcomes at eight maternity wards throughout Botswana accounting for close to half of all nationwide deliveries, Rebecca Zash of Beth Israel Deaconess Medical Center told participants on Monday at the 9th International AIDS Society Conference on HIV Science (IAS 2017).

And, a French study of birth outcomes in women exposed to raltegravir during pregnancy found no excess risk of adverse birth outcomes compared to other antiretroviral regimens.

Dolutegravir and raltegravir are HIV integrase inhibitors and the drugs are being prescribed more frequently as preferred options for first-line treatment. The findings presented this week are the first large surveys of adverse birth outcomes in women exposed to either drug.